MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines

Abstract The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from 20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus on approaches to accelerate second-generation malaria vaccine development...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Vannice Kirsten S, Brown Graham V, Akanmori Bartholomew D, Moorthy Vasee S
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2012
Subjects:
Global
Malaria
WHO
Malaria vaccine
Elimination
Vaccine research
Surveillance
Clinical trials
Field trials
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/1475-2875-11-372
https://doaj.org/article/e5bb5d6f469145e5aa419ebe9a3ffd26
Description
Summary:Abstract The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from 20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus on approaches to accelerate second-generation malaria vaccine development, and to discuss the need to update the vision and strategic goal of the Malaria Vaccine Technology Roadmap. This article summarizes the forum, which included reviews of leading Plasmodium falciparum vaccine candidates for pre-erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines. Other major topics included vaccine candidates against Plasmodium vivax , clinical trial site capacity development in Africa, trial design considerations for a second-generation malaria vaccine, adjuvant selection, and regulatory oversight functions including vaccine licensure.

Similar Items